- Home
- STXS vs IPHA Comparison
STXS vs IPHA Comparison
Compare STXS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STXS
- IPHA
- Stock Information
- Founded
- STXS 1990
- IPHA 1999
- Country
- STXS United States
- IPHA France
- Employees
- STXS N/A
- IPHA N/A
- Industry
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- STXS Health Care
- IPHA Health Care
- Exchange
- STXS Nasdaq
- IPHA Nasdaq
- Market Cap
- STXS N/A
- IPHA 148.3M
- IPO Year
- STXS 2004
- IPHA 2019
- Fundamental
- Price
- STXS $2.19
- IPHA $1.77
- Analyst Decision
- STXS Strong Buy
- IPHA Strong Buy
- Analyst Count
- STXS 2
- IPHA 1
- Target Price
- STXS $4.50
- IPHA $11.50
- AVG Volume (30 Days)
- STXS 337.8K
- IPHA 39.3K
- Earning Date
- STXS 03-03-2025
- IPHA 03-20-2025
- Dividend Yield
- STXS N/A
- IPHA N/A
- EPS Growth
- STXS N/A
- IPHA N/A
- EPS
- STXS N/A
- IPHA N/A
- Revenue
- STXS $25,143,000.00
- IPHA $36,202,722.00
- Revenue This Year
- STXS $3.73
- IPHA N/A
- Revenue Next Year
- STXS $54.27
- IPHA $101.65
- P/E Ratio
- STXS N/A
- IPHA N/A
- Revenue Growth
- STXS N/A
- IPHA N/A
- 52 Week Low
- STXS $1.66
- IPHA $1.29
- 52 Week High
- STXS $3.29
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- STXS 48.66
- IPHA 47.64
- Support Level
- STXS $2.21
- IPHA $1.63
- Resistance Level
- STXS $2.22
- IPHA $1.78
- Average True Range (ATR)
- STXS 0.13
- IPHA 0.10
- MACD
- STXS -0.01
- IPHA -0.02
- Stochastic Oscillator
- STXS 23.19
- IPHA 48.57
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.